Skip to main content
Clinical Trials/NCT07269262
NCT07269262
Recruiting
Not Applicable

Feasibility and Acceptability of a Mobile Application "SUPPORT-T" to Increase Equitable Access to Palliative Care in Patients With Progressive Pulmonary Fibrosis (PPF) and Their Caregivers

Medical University of South Carolina1 site in 1 country170 target enrollmentStarted: January 13, 2026Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
170
Locations
1
Primary Endpoint
Feasibility of Disease Preparedness

Overview

Brief Summary

This pilot randomized controlled trial evaluates the feasibility, acceptability, and accessibility of SUPPORT-T, a digitally delivered palliative care intervention for patients with Progressive Pulmonary Fibrosis (PPF) and their caregivers. The intervention includes a 9-week digital application guided by a nurse interventionist and quarterly virtual support groups over one year. Participants will be recruited from rural South Carolina and urban New York City. The study compares SUPPORT-T to Enhanced Usual Care and aims to inform a future multi-site trial.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults ≥18 years
  • Confirmed diagnosis of PPF
  • English or Spanish speaking
  • Caregiver Inclusion Criteria:
  • adult, ≥ 18 years old
  • Designated and identified by patient as providing most of the emotional, financial, and/or physical support (i.e., the individual most involved in care, does not have to live with patient)
  • Able to speak and understand English.

Exclusion Criteria

  • Not provided

Arms & Interventions

SUPPORT-T Intervention Arm

Experimental

Participants in the intervention arm will have a telehealth preparatory visit scheduled 1 week later (Week 2) with the Study Coordinator and will be provided with the study number to call with questions.

SUPPORT-T will be delivered biweekly at TeleHealth Visits 1-4 via a secure interface via MUSC telehealth platform. The nurse interventionist will receive results from the REDCap survey after each TH visit and contact the patient biweekly after each TH visit using the MUSC Telehealth and/or Health platform. The nurse interventionist will be available for any questions and communicate with the participants via bi-directional texts (SC will maintain a log of those texts).

• All participants will complete questionnaires at Week 1, Week 9, Month 6, and Month 12

Intervention: SUPPORT-T Educational Intervention (Other)

Enhanced Usual Care Control Group

No Intervention
  • Participants in the enhanced usual care arm will receive printed education materials from the Pulmonary Fibrosis Foundation (PFF) and the nurse interventionist's contact information.
  • All participants will complete questionnaires at Week 1, Week 9, Month 6, and Month 12

Outcomes

Primary Outcomes

Feasibility of Disease Preparedness

Time Frame: 10 months

Feasibility outcomes include number of participants recruited weekly, number of participants who declined, and number of participants who did not meet eligibility requirements, data collection procedures, and participant responses. Feasibility data will inform future studies on approaches for recruitment and retention, study procedures, and timing and participant capacity to complete surveys/interviews.

Disease Preparedness Feasibility

Time Frame: 10 months

Feasibility outcomes include number of participants recruited weekly, number of participants who declined, and number of participants who did not meet eligibility requirements, data collection procedures, and participant responses. Feasibility data will inform future studies on approaches for recruitment and retention, study procedures, and timing and participant capacity to complete surveys/interviews.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Kathleen Lindell

Associate Professor-Faculty

Medical University of South Carolina

Study Sites (1)

Loading locations...

Similar Trials